Latest Healthcare News

Cyclopharm has landed a major US expansion deal with University Hospitals Cleveland, deploying Technegas® across 11 sites simultaneously and boosting its recurring revenue base in the Midwest.

Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.

INOVIQ Ltd has revealed significant sample quality problems in its EXO-OC ovarian cancer diagnostic study, prompting a technical review and a refined development approach while maintaining its dual commercialisation strategy.

HeraMED's Phase 1 pilot with Lee Health confirms strong patient adoption and operational efficiency for its digital maternity care platform, setting the stage for broader US rollout.

Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.

Pacific Edge edges closer to Medicare reimbursement for its bladder cancer tests while its Asia Pacific operations show rising test volumes and improved margins, signaling a path toward profitability.

Ryman Healthcare reported steady retirement living sales in Q1 FY27 with a 7% rise in net resales, buoyed by serviced apartments. The company remains on track for FY27 build targets and sees robust aged care occupancy despite housing market headwinds.

Cleo Diagnostics (ASX:COV) has entered the analytical validation phase for its ovarian cancer test, progressing toward an FDA 510(k) submission expected in early 2027.

Visionflex Group turned the corner with positive operating cash flow in Q4 FY26 and the launch of its unattended access capability, while securing new contracts to expand its virtual healthcare footprint.

Orthocell Limited has posted record revenue for FY2026, driven by strong sales growth of Remplir™ and Striate+™ products in Australia, the US, and new international markets, supported by a robust $44.1 million cash position.

OncoSil Medical has completed key manufacturing validation cycles with Cyclotek, paving the way for scalable Australian production of its OncoSil™ device. With a $2.1 million capital investment, the company aims to boost margins and supply chain control ahead of commercial launch in late 2026.

Cryosite Limited reported an 18% rise in FY2026 revenue to $16.7 million, with EBITDA growing 27% amid completed and ongoing facility expansions. The company aims to convert new capacity into client growth in FY2027.